Aberrant activation of Wnt/β-catenin signaling plays a central role in the pathogenesis of a
wide variety of malignancies and is typically caused by mutations in core Wnt pathway …

Although therapeutic strategies have been adapted to age and comorbidities for a long time,
almost all multiple myeloma (MM) patients currently receive similar treatment, whatever their …

In multiple myeloma malignant plasma cells expand within the bone marrow. Since this site
is well-perfused, a rapid dissemination of “fitter” clones may be anticipated. However, an …

Multiple myeloma, a plasma cell malignancy, is the second most common blood cancer.
Despite extensive research, disease heterogeneity is poorly characterized, hampering …

We analyzed whole genomes of unique paired samples from smoldering multiple myeloma
(SMM) patients progressing to multiple myeloma (MM). We report that the genomic …

In multiple myeloma, next-generation sequencing (NGS) has expanded our knowledge of
genomic lesions, and highlighted a dynamic and heterogeneous composition of the tumor …

Despite tremendous improvements in the outcome of patients with multiple myeloma in the
past decade, high-risk patients have not benefited from the approval of novel drugs. The …

Clonal evolution drives tumor progression, chemoresistance and relapse in cancer. Little is
known about clonal selection induced by therapeutic pressure in multiple myeloma. To …

The diagnosis of multiple myeloma can be challenging, even for experienced physicians,
and requires close collaboration between numerous disciplines (orthopedics, radiology …

6 Frezzato M, Giaretta I, Madeo D, Rodeghiero F. Identical IGHV-DJ gene rearrangement
may precede the clinical onset of chronic lymphocytic leukemia by several years. Am J …